Lisa Olson - Magenta Therapeutics Head Officer

MGTADelisted Stock  USD 0.82  0.03  3.80%   

Insider

Lisa Olson is Head Officer of Magenta Therapeutics
Age 63
Phone857 242 0170
Webhttps://www.magentatx.com

Magenta Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2885) % which means that it has lost $0.2885 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6534) %, meaning that it created substantial loss on money invested by shareholders. Magenta Therapeutics' management efficiency ratios could be used to measure how well Magenta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Magenta Therapeutics currently holds 29.96 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Magenta Therapeutics has a current ratio of 10.02, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Magenta Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Angela MDSpero Therapeutics
N/A
David HanleyNuvation Bio
54
FMEDSCI MDAchilles Therapeutics PLC
49
MBA MDSpero Therapeutics
43
Uri MDAssembly Biosciences
52
MD FACPNextCure
71
Sergey YurasovNuvation Bio
51
MHROD SHRMSCPAssembly Biosciences
N/A
Timothy MooreInstil Bio
63
Ian CritchleySpero Therapeutics
N/A
Bronson CrouchInstil Bio
51
Michael MSBANextCure
63
Iraj AliAchilles Therapeutics PLC
49
Satyavrat CFASpero Therapeutics
51
Thomas TemplemanNuvation Bio
60
CPA CPANextCure
61
James BradySpero Therapeutics
N/A
Sandeep MDInstil Bio
55
Robert CouttsAchilles Therapeutics PLC
40
Sergio QuezadaAchilles Therapeutics PLC
49
Gary HattersleyNuvation Bio
57
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Magenta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people. Magenta Therapeutics (MGTA) is traded on NASDAQ Exchange in USA and employs 67 people.

Management Performance

Magenta Therapeutics Leadership Team

Elected by the shareholders, the Magenta Therapeutics' board of directors comprises two types of representatives: Magenta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Magenta. The board's role is to monitor Magenta Therapeutics' management team and ensure that shareholders' interests are well served. Magenta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Magenta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Caren Deardorf, Chief Officer
David Nichols, Chief Officer
Jason DPHIL, CEO, CoFounder
Catherine Monaghan, Head Operations
Lisa Olson, Head Officer
MBA JD, Chief Treasurer
Jim Haney, Director Relations
Lyndsey Scull, Director Communications
Kristen Stants, Chief Officer

Magenta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Magenta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Magenta Stock

If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency